Abstract:To retrospectively investigate the feasibility of radiofrequency ablation (RFA) in treating advanced hepatocellular carcinoma (HCC) using standard ultrasound-guided percutaneous RFA.A total of 655 patients with unresectable advanced HCC underwent ultrasound-guided percutaneous RFA therapy at our institution between July 2000 to September 2001. Ninety-two of those patients, representing 136 tumors, were selected for analysis based on the following criteria: presence of UICC/AJCC-TNM (6th edition) stage III and IV advanced HCC, (III: n=82 patients, with 126 tumors; IV: n=10 patients, with 10 tumors); extensive portal vein or inferior vena cava tumor thrombus; extrahepatic metastasis after surgical resection; and complete follow-up data. Follow-up consisted of enhanced computed tomography (CT) performed at one month post-RFA treatment, then every three months. Contrast-enhanced ultrasound (CEUS) was performed in 51 (55.4%) patients before RFA. The standard treatment using optimal strategies were applied in (72.8%) 67 patients. The established strategies included: (1) select RFA indications based on CEUS results; (2) design radical protocols based on invasive range showed by CEUS; (3) multiple overlapping ablations based on mathematical protocols; (4) two or three bipolar RFA electrodes with three-dimensional localization; (5) color ultrasound-guided percutaneous ablation of tumor feeding artery (PAA)/transcatheter arterial chemoembolization (TACE) + RFA for HCC with rich supply. The other 25 patients (27.2 %) were treated with conventional RFA protocols. The ablation procedure was considered a success if no abnormal enhancement or wash-out was detected in the treated area on the CT scan at one month. All patients had received liver protection treatments following RFA. Chi-squared test or Fisher's exact test were used to compare the early complete tumor necrosis rates and the local recurrence rates. Survival was estimated by Kaplan-Meier analysis and log-rank test. P less than 0.05 was considered statistically significant.The RFA-treated tumors ranged in size from 1.5 to 7.0 cm (average: 4.5 cm). Fifty-nine patients had solitary tumor, and the remaining 33 had multiple tumors (2 to 4 tumors). Patients were classified by Child-Pugh score as A (n=58), B (n=32) and C (n=2). Early complete tumor necrosis rate after initial RFA was 90.4% (123/136 tumors). Serious complications developed in two patients (2.2%). No treatment-related death occurred. Follow-up ranged from 3-134 months. Local recurrence rate was 16.9% (23/136 tumors). The 1-, 3- and 5-year overall survival rates were 83.3%, 48.3% and 21.9%, respectively, and the median survival time was 35 months. Stratification analysis indicated the early complete tumor necrosis rate was higher in groups of patients with Child-Pugh A score (98.3%) , CEUS administration (98.0%), and standard treatment (97.0%). The local recurrence rate was lower in groups of patients with tumors less than or equal to 3.0 cm (5.9%), CEUS administration (11.8%), and standard treatment (16.4%). The 5-year survival was significantly higher in patients with Child-Pugh A, tumors less than or equal to 3.0 cm, CEUS administration, and standard treatment (all, P less than 0.05).RFA treatment of patients with advanced HCC, tumors less than 7.0 cm, and without thrombosis in the main vessels was efficacious. The RFA treatment strategy and subsequent liver protection therapy in RFA may improve survival.

Short and Long Term Efficacy of High Intensity Focused Ultrasound Therapy for Advanced Hepatocellular Carcinoma

Clinical Effect of High Intensity Focused Ultrasound Therapy for Advanced Hepatocellular Carcinoma

Follow-up of High-Intensity Focused Ultrasound Treatment for Patients with Hepatocellular Carcinoma.

Therapeutic effectiveness of high-intensity focused ultrasound (HIFU) ablation in patients with unresectable hepatocellular carcinoma.

Efficacy Analysis of High Intensity Focused Ultrasound on Advanced Liver Cancer

Effect of High Intensity Focused Ultrasound on the Patients with Hepatocellular Carcinoma:Preliminary Report

Clinical effects of high intensity focused ultrasound in treatment of advanced liver cancer: analysis of 254 cases

High-intensity focused ultrasound alone or combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with unsuitable indications for hepatectomy and radiofrequency ablation: a phase II clinical trial

Evaluating the long-term survival benefits of high intensity focused ultrasound ablation for hepatocellular carcinoma with portal vein tumor thrombus: a single center retrospective study

Analysis of Clinical Effect of High-Intensity Focused Ultrasound on Liver Cancer

High intensity focused ultrasound ablation for patients with inoperable liver cancer.

Multidisciplinary Treatment with Chemotherapy, Targeted Drug, and High-Intensity Focused Ultrasound in Advanced Pancreatic Carcinoma

Therapeutic effects and prognostic factors in high-intensity focused ultrasound combined with chemoembolisation for larger hepatocellular carcinoma.

The Efficacy Of A New High-Intensity Focused Ultrasound Therapy For Metastatic Pancreatic Cancer

Efficacy of extracorporeal ultrasound-guided high intensity focused ultrasound: An evaluation based on controlled trials in China

Long-Term Outcome of High-Intensity Focused Ultrasound in Advanced Pancreatic Cancer

Sequential Transcatheter Arterial Chemoembolization, Three-Dimensional Conformal Radiotherapy, and High-Intensity Focused Ultrasound Treatment for Unresectable Hepatocellular Carcinoma Patients

Effects of High‐intensity Focused Ultrasound and Anti‐angiogenic Agents on the Ablation of Experimental Liver Cancers

High-intensity focused ultrasound versus transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis

High-intensity focused ultrasound treatment for patients with unresectable pancreatic cancer.

Efficacy of radiofrequency ablation to treat advanced hepatocellular carcinoma]